ARCHIVES

Phase III Trial Would Give Clearer Picture of C225 Role

This article is from The Cancer Letter archive.

Vol. 28 No. | March 8, 2002

Download PDF Visit The Full Archive

Related Articles

DCCP Board Okays Noncompetitive Procurements

June 11, 1982

Why Four? NCI Official Challenged To Explain Rational For Proposed Number Of Groups

March 25, 2011

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

Letter: Biostatistics Directors Invited To Share Concerns

June 7, 1996

DCT To Announce June 1 Guidelines For CREG Program In Cell Kinetics Related To Chemo, Radiotherapy

April 25, 1975

NCI Encourages IP Chemo For Stage III Ovarian Cancer

January 27, 2006